Portland, OR, December 01, 2015 --(PR.com
)-- A new study recently published in the journal Scientific Reports by Nature Publishing Group shows that Lightair’s patented IonFlow technology effectively prevents the spread of airborne transmitted viruses and is highly efficient in capturing small particles. The study was carried out by researchers at Karolinska Institute (KI) and University of Linköping (LiU) in Sweden. Karolinska Institute is one of the world's leading medical universities. Since 1901 the Nobel Assembly at Karolinska Institute has selected the Nobel laureates in Physiology or Medicine.
The viruses, calicivirus, rotavirus and influenza virus, used in the study are of great clinical and economic importance since they represent and was used as surrogates for viruses that cause among other diseases, different types of influenza, the “winter vomiting disease,” diarrhea and gastroenteritis. Diseases affecting millions of people each year. The viruses circulate worldwide and can affect anybody in any age group. Seasonal influenza causes severe disease in an estimated 3-5 million people worldwide every year and is responsible for 250,000 – 500,000 deaths annually, according to WHO.
The effectiveness of the Lightair IonFlow technology was evaluated in several studies, including experiments on guinea pigs, which were exposed to influenza A (strain Panama 99). The results showed that none of the guinea pigs, exposed to infected animals, became infected when the ionizer device was active, whereas three out of four exposed animals became infected when the ionizer was inactive. Furthermore, it was shown that the IonFlow technology is highly efficient in capturing viruses even when there are only small amounts of viruses in the air as well as very small particles, so called nanoparticles. The study states that “this device enables unique possibilities to analyze air and prevent the spread of infectious diseases, which provides a wide medical and clinical application.”
“Lightair is in many ways a true pioneer in the field of air purification. We are thrilled to see the test result, since it confirms other tests which show that our products are very effective against the dangerous nanoparticles and ultra-fine particles,” said Roger Sogge, CEO at Lightair. “This will enable us to strengthen our message to the public that we can help reduce the serious problems that air pollution causes. We will continue our dedication to improving people's health and comfort by offering the best, most versatile indoor air quality products in the market.”
Lightair IonFlow’s unique ionization technology offers a new solution to prevent aerosol-transmitted influenza infections by preventing the spread of airborne transmitted viruses without generating ozone. The high volume of ion production, easy handling, low cost, ozone-free production of ions, robustness, high efficiency and low-voltage (12 volt) of the Lightair IonFlow technology enables large-scale use suitable for distribution in airplanes, hospitals, day-care centers, school environments and other public places as well as homes.
The full report may be viewed at:
For further information, please contact:
Roger Sogge, CEO
Mia Pang, Marketing & Communications Coordinator
Mobile: +46 72 500 45 60
Lightair specializes in enhancing indoor air quality in residential, commercial and industrial spaces through its revolutionary patented technologies. The company was established 2006 in Sweden and now has distribution in Europe, Asia, Middle East and North America. The products are developed on the Lightair IonFlow technology, which makes them filter free, silent and no ozone emitted.
Lightair stands for innovation, quality and design and through extensive and ongoing research we work to develop efficient, functional and well-designed applications.